OTC Markets Group Inc. (OTCQX: OTCM) and PR Newswire were joined by the UK’s Investor Relations Society in welcoming senior investor relations professionals to the latest instalment of their successful “No Blank Screens” series. The goal of the breakfast forum was to help educate European companies with global vision about the OTCQX® Best and OTCQB® Venture Marketplaces in the US, and to provide guidance and best practice tips on effectively engaging US investors. The event was held in the historic, Grade II listed One Moorgate Place in central London on 2nd July.
To view the Multimedia News Release, please go to http://www.multivu.com/players/English/7571051-trans-atlantic-information-flow/
Today, Valvoline™, a brand of Ashland Inc., announced the wide-scale availability of NextGen™ motor oil. The new formula is made from 50 percent recycled oil and delivers 100 percent Valvoline engine protection. NextGen motor oil is great for engines and better for the environment, exceeding industry specifications with reduced environmental impact compared to non-recycled motor oil.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/valvoline-nextgen/49478/
Kraton Performance Polymers, Inc. (NYSE: “KRA”), a leading global producer of styrenic block copolymers and other engineered polymers will present a paper and exhibit at Techtextil, June 11-13 in Frankfurt, Germany highlighting NEXAR™ polymer coatings. Kraton will be located in Hall 3.1 booth number J33. Dr. Richard Blackwell, Senior Scientist with Kraton Polymers will host a technical presentation entitled “New Selectively Sulfonated Pentablock Copolymer Imparts Cooling Comfort to Textiles and Nonwovens.” The presentation is scheduled for Wednesday, June 12th at 12:20 pm – 12:45 pm.
To view Multimedia News Release, go to http://www.multivu.com/mnr/45712-kraton-techtextil-frankfurt-2013-nexar-cooling-technology
Everyday Health, Inc. (NYSE: EVDY), today announced the launch of the What to Expect Pregnancy Clock Apple Watch™ app. Everyday Health, Inc. is a leading digital health and wellness company that operates the digital assets of What to Expect, Heidi Murkoff’s world-renowned pregnancy and parenting brand.
Designed specifically for the Apple Watch, the What to Expect Pregnancy Clock delivers a pregnancy countdown (to the second) – with weekly updates and visual growth milestones to track progress, actionable tips and notifications synchronized to the baby’s growth and development, and other relevant pregnancy information on demand. All of this gives expectant parents-to-be convenient, personalized, and discreet access to essential information about their baby’s development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7221451-pregnancy-clock-apple-watch-app/
Dorel Juvenile Group (DJG), Inc., a division of Dorel Industries (TSX: DII.B, DII.A), and the nation’s largest juvenile products manufacturer, announces the launch of a new, premium collection - the S1 Series by Safety 1st - offering premium design with safety in mind. S1 Series is the first collection of its kind designed to meet exceptional standards of both safety and style, providing parents with high quality products for travel, meal time, and play. The line, which includes a travel system, play yard and high chair, is now available exclusively at Babies“R”Us stores nationwide and online at Babiesrus.com.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/safety1st/48342/
Nutrisystem, Inc. (NASDAQ: NTRI), the number one home delivery weight loss company, announced today that it is revamping its programs by incorporating its highest scoring, best tasting fresh frozen gourmet foods into all of its weight loss plans at the lowest price in the Company’s history. Part of Nutrisystem’s “Hooray You! New You Revolution” initiative is to empower and celebrate the success of its members, and with these significant changes it will make Nutrisystem® weight loss programs more accessible to a wider audience than ever before.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/nutrisystem/47901/
The Yankee Candle Company, Inc., the world’s largest manufacturer of premium scented candles, today announced the launch of two new fragrances and the return of three favorites in its popular limited edition Man Candles collection. Just in time for Father’s Day, Camouflage and On Tap™ join last year’s introduction MMM, Bacon!™ and original Man Candles Man Town™ and Riding Mower™. The Man Candles collection, which was an instant hit when it debuted in 2012, was created uniquely for men to enjoy in their “man town,” wherever that may be in the house. These limited edition fragrances are available now at Yankee Candle’s over 500 retail stores, at www.yankeecandle.com and select specialty retailers and gift shops. Yankee Candle is launching a series of social media contests offering consumers the chance to win samples of the Man Candles III collection!
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7221651-yankee-candle-heads-outdoors-new-man-candles-fragrances
ViaSat Inc. (NASDAQ: VSAT) has announced that International Launch Services has successfully launched ViaSat-1, the highest capacity satellite in the world. The Proton M launch vehicle lifted off from pad 39 at the Baikonur Cosmodrome, Kazakhstan, at 11:48 am (PDT) October 19, followed by spacecraft separation from the launch vehicle at 9:12 pm, signal acquisition shortly thereafter, and finally deployment of both the north and south solar arrays.
To view Multimedia News Release, go to http://www.multivu.com/players/English/47671-viasat-satellite-launch/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
To help professionals and do-it-yourselfers weatherize and make home improvements faster, DAP Products Inc. today announced the introduction of the newest innovation in premium sealants. The newly-formulated DAP® 3.0™ line establishes first-to-market technology with high-performance sealants that are both paintable and water resistant in 30 minutes. In addition, DAP® 3.0™ is low odor, VOC-compliant (volatile organic compounds) and backed by a lifetime guarantee.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57526-dap-introduces-newest-innovation-in-high-performance-sealants
17.6 billion. That’s how many times U.S. shoppers visited brick-and-mortar stores during the 2013 holiday shopping season. That’s a lot of purchases – and a lot of receipts changing hands. Holiday sales are expected to rise 4.1 percent this November and December, meaning even more shoppers will be visiting stores and receiving gift receipts.
Just in time for the 2014 holiday shopping rush, a new receipt paper from Appvion, Inc., made with vitamin C instead of phenols like bisphenol A (BPA) and bisphenol S (BPS), is available to stores nationwide. Now shoppers can focus on finding that perfect gift instead of worrying about phenols in receipts they might receive.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7362451-appvion-launches-first-thermal-alpha-free-receipt-paper-using-vitamin-c-for-2014-holiday-shopping-season/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled,
